News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
422,021 Results
Type
Article (18298)
Company Profile (122)
Press Release (403593)
Multimedia
Podcasts (68)
Webinars (13)
Section
Business (135602)
Career Advice (884)
Deals (24547)
Drug Delivery (77)
Drug Development (47540)
Employer Resources (67)
FDA (8810)
Job Trends (8694)
News (221093)
Policy (19218)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (751)
Accelerated approval (16)
Adcomms (11)
Allergies (80)
Alliances (31459)
ALS (76)
Alzheimer's disease (700)
Antibody-drug conjugate (ADC) (129)
Approvals (9033)
Artificial intelligence (256)
Autoimmune disease (68)
Automation (16)
Bankruptcy (212)
Best Places to Work (6248)
BIOSECURE Act (9)
Biosimilars (126)
Biotechnology (54)
Bladder cancer (66)
Brain cancer (31)
Breast cancer (230)
Cancer (1990)
Cardiovascular disease (200)
Career advice (774)
Career pathing (16)
CAR-T (102)
CDC (13)
Cell therapy (293)
Cervical cancer (13)
Clinical research (41253)
Collaboration (934)
Compensation (601)
Complete response letters (37)
COVID-19 (1059)
CRISPR (54)
C-suite (606)
Cystic fibrosis (76)
Data (2826)
Denatured (20)
Depression (66)
Diabetes (202)
Diagnostics (3077)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (19)
Drug discovery (129)
Drug pricing (120)
Drug shortages (14)
Duchenne muscular dystrophy (108)
Earnings (60626)
Editorial (27)
Employer branding (9)
Employer resources (65)
Events (66110)
Executive appointments (741)
FDA (10352)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (9)
Funding (681)
Gene editing (89)
Generative AI (22)
Gene therapy (257)
GLP-1 (527)
Government (1922)
Grass and pollen (4)
Guidances (266)
Healthcare (7672)
HIV (22)
Huntington's disease (17)
IgA nephropathy (41)
Immunology and inflammation (100)
Immuno-oncology (21)
Indications (65)
Infectious disease (1152)
Inflammatory bowel disease (97)
Inflation Reduction Act (7)
Influenza (35)
Intellectual property (133)
Interviews (111)
IPO (11109)
IRA (33)
Job creations (2680)
Job search strategy (688)
JPM (31)
Kidney cancer (12)
Labor market (33)
Layoffs (270)
Leadership (18)
Legal (5139)
Liver cancer (40)
Longevity (9)
Lung cancer (266)
Lymphoma (203)
Machine learning (15)
Management (24)
Manufacturing (483)
MASH (101)
Medical device (4929)
Medtech (4945)
Mergers & acquisitions (14109)
Metabolic disorders (605)
Multiple sclerosis (60)
NASH (17)
Neurodegenerative disease (122)
Neuropsychiatric disorders (47)
Neuroscience (1275)
Neurotech (1)
NextGen: Class of 2026 (2846)
Non-profit (1313)
Now hiring (19)
Obesity (287)
Opinion (167)
Ovarian cancer (52)
Pain (124)
Pancreatic cancer (82)
Parkinson's disease (110)
Partnered (16)
Patents (252)
Patient recruitment (184)
Peanut (17)
People (41844)
Pharmaceutical (65)
Pharmacy benefit managers (18)
Phase 1 (11429)
Phase 2 (17722)
Phase 3 (14988)
Pipeline (3227)
Policy (150)
Postmarket research (1703)
Preclinical (4629)
Press Release (72)
Prostate cancer (108)
Psychedelics (19)
Radiopharmaceuticals (180)
Rare diseases (470)
Real estate (3798)
Recruiting (25)
Regulatory (14370)
Reports (24)
Research institute (835)
Resumes & cover letters (122)
Rett syndrome (24)
RNA editing (7)
RSV (22)
Schizophrenia (95)
Series A (118)
Series B (90)
Service/supplier (2)
Sickle cell disease (51)
Special edition (11)
Spinal muscular atrophy (92)
Sponsored (13)
Startups (2165)
State (2)
Stomach cancer (6)
Supply chain (55)
Tariffs (68)
The Weekly (46)
Vaccines (335)
Venture capital (39)
Weight loss (165)
Women's health (34)
Worklife (4)
Date
Today (13)
Last 7 days (310)
Last 30 days (1044)
Last 365 days (16120)
2026 (1821)
2025 (16478)
2024 (19552)
2023 (22839)
2022 (31122)
2021 (32731)
2020 (30914)
2019 (24003)
2018 (18565)
2017 (19692)
2016 (18660)
2015 (22629)
2014 (18583)
2013 (15578)
2012 (16810)
2011 (17585)
2010 (16534)
Location
Africa (454)
Alabama (34)
Alaska (3)
Arizona (124)
Arkansas (4)
Asia (27574)
Australia (3692)
California (5702)
Canada (2021)
China (665)
Colorado (276)
Connecticut (257)
Delaware (169)
Europe (55320)
Florida (990)
Georgia (129)
Hawaii (1)
Idaho (29)
Illinois (458)
India (55)
Indiana (293)
Iowa (12)
Japan (313)
Kansas (90)
Kentucky (29)
Louisiana (12)
Maine (53)
Maryland (617)
Massachusetts (4427)
Michigan (133)
Minnesota (294)
Mississippi (2)
Missouri (57)
Montana (18)
Nebraska (14)
Nevada (57)
New Hampshire (24)
New Jersey (1976)
New Mexico (11)
New York (1513)
North Carolina (882)
North Dakota (5)
Northern California (2785)
Ohio (174)
Oklahoma (7)
Oregon (23)
Pennsylvania (1108)
Puerto Rico (14)
Rhode Island (25)
South America (682)
South Carolina (23)
Southern California (2294)
Tennessee (103)
Texas (843)
United States (21150)
Utah (142)
Virginia (208)
Washington D.C. (47)
Washington State (431)
West Virginia (3)
Wisconsin (75)
Wyoming (1)
422,021 Results for "chong kun dang pharmaceutical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for Gastroparesis
Aclipse Therapeutics announced today that it has signed an exclusive license agreement with Seoul, South Korea-based Chong Kun Dang Pharmaceutical Corporation (“CKD”).
September 14, 2023
·
4 min read
Business
Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule
For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.
November 7, 2023
·
2 min read
·
Tristan Manalac
Drug Development
Healis Therapeutics’ asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A.
February 27, 2024
·
2 min read
Business
OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation
OSE Immunotherapeutics, announced a new licensing deal with Chong Kun Dang Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea.
November 7, 2019
·
6 min read
Press Releases
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
·
11 min read
Business
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
March 18, 2024
·
6 min read
Business
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
InflaRx N.V. today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.
June 28, 2023
·
7 min read
Press Releases
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
January 6, 2026
·
6 min read
Press Releases
Alkeus Pharmaceuticals to Present Corporate Update at the 44th Annual J.P. Morgan Healthcare Conference
January 9, 2026
·
1 min read
Press Releases
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions
January 8, 2026
·
3 min read
1 of 42,203
Next